Iconovo AB (publ) (STO:ICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.100
-0.025 (-2.22%)
Jan 21, 2026, 5:15 PM CET
-76.03%
Market Cap59.69M
Revenue (ttm)16.79M
Net Income (ttm)-41.23M
Shares Out53.06M
EPS (ttm)-1.41
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume323,667
Average Volume136,851
Open1.165
Previous Close1.125
Day's Range1.065 - 1.170
52-Week Range1.045 - 5.180
Beta0.44
RSI36.99
Earnings DateFeb 27, 2026

About Iconovo AB

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for ... [Read more]

Sector Healthcare
Founded 2013
Employees 25
Stock Exchange Nasdaq Stockholm
Ticker Symbol ICO
Full Company Profile

Financial Performance

In 2024, Iconovo AB's revenue was 24.00 million, a decrease of -14.62% compared to the previous year's 28.11 million. Losses were -41.14 million, -10.36% less than in 2023.

Financial Statements